Researchers from the London Ataxia Centre at UCL/UCLH (UK), and Mayo Clinic (US), published an research article about a novel test that can measure the faulty protein levels in people with Spinocerebellar Ataxia 3 (SCA3). Measuring faulty protein levels can be extremely helpful to assess whether a treatment is effective for that particular condition.
Dr Hector Garcia-Moreno at UCL, joint lead author on the paper, said: “This assay constitutes a robust biological marker and will be used for the discovery of new treatments and for the interventional trials that are currently in the pipeline for SCA3”.
Professor Paola Giunti, Head of the London Ataxia Centre said: “It is exciting to have closely collaborated to the development of this crucial test that will contribute to the readiness of clinical trials in SCA3, a condition for which, so far, we do not have a cure. This will facilitate the discovery and implementation of new molecules for the treatment of this condition.”
Posted on 30/10/2020